GWP42003 + GWP42003 + GWP42004 + Placebo

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 32/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Dyslipidemias

Conditions

Dyslipidemias, Diabetes Mellitus, Type 2

Trial Timeline

Oct 1, 2010 → Sep 1, 2012

NCT ID

NCT01217112

About GWP42003 + GWP42003 + GWP42004 + Placebo

GWP42003 + GWP42003 + GWP42004 + Placebo is a phase 2 stage product being developed by Jazz Pharmaceuticals for Dyslipidemias. The current trial status is completed. This product is registered under clinical trial identifier NCT01217112. Target conditions include Dyslipidemias, Diabetes Mellitus, Type 2.

What happened to similar drugs?

6 of 6 similar drugs in Dyslipidemias were approved

Approved (6) Terminated (0) Active (0)

✅Rosuampin 10/5mg + Rosuampin 20/5mg + Amlodipine/Atorvastatin 5/20mgYuhanApproved

✅Atorvastatin + AtorvastatinPfizerApproved

✅AtorvastatinPfizerApproved

✅Atorvastatin + Atorvastatin + AtorvastatinPfizerApproved

✅AtorvastatinPfizerApproved

✅Atorvastatin + Atorvastatin + AtorvastatinPfizerApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01217112	Phase 2	Completed	Oct 1, 2010	Sep 1, 2012	Dyslipidemias

Competing Products

15 competing products in Dyslipidemias

See all competitors

Product	Company	Stage	Hype Score
LY3202328 + Placebo + Atorvastatin + Simvastatin	Eli Lilly	Phase 1	29
Rosuampin 10/5mg + Rosuampin 20/5mg + Amlodipine/Atorvastatin 5/20mg	Yuhan	Approved	43
LY3475766 - IV + LY3475766 - SC + Placebo - IV + Placebo - SC	Eli Lilly	Phase 1	29
LY3885125 + Placebo	Eli Lilly	Phase 1	21
LY3561774 + Placebo	Eli Lilly	Phase 1	29
LY3561774 + Placebo	Eli Lilly	Phase 2	35
LY2484595 + Placebo + Atorvastatin	Eli Lilly	Phase 2	35
Atorvastatin + Atorvastatin	Pfizer	Approved	43
Atorvastatin	Pfizer	Approved	43
Atorvastatin + Atorvastatin + Atorvastatin	Pfizer	Approved	43
Vupanorsen + Placebo	Pfizer	Phase 2	35
Atorvastatin	Pfizer	Approved	43
Atorvastatin + Atorvastatin + Atorvastatin	Pfizer	Approved	43
ARO-APOC3	Arrowhead Pharmaceuticals	Phase 2	32
ARO-ANG3 + sterile normal saline (0.9% NaCl)	Arrowhead Pharmaceuticals	Phase 1	26